These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

629 related items for PubMed ID: 25367661

  • 1. Agomelatine augmentation in obsessive compulsive disorder: a preliminary report.
    Tzavellas E, Karaiskos D, Ilias I, Liappas I, Paparrigopoulos T.
    Psychiatriki; 2014; 25(3):179-84. PubMed ID: 25367661
    [Abstract] [Full Text] [Related]

  • 2. Agomelatine augmentation of sertraline in the treatment of moderate to severe obsessive-compulsive disorder: a randomized double-blinded placebo-controlled clinical trial.
    Shokrani M, Askari S, Eissazade N, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M.
    BMC Psychiatry; 2023 Sep 21; 23(1):686. PubMed ID: 37735631
    [Abstract] [Full Text] [Related]

  • 3. Aripiprazole augmentation of serotonin reuptake inhibitors in treatment-resistant obsessive-compulsive disorder: a 10-week open-label study.
    Ak M, Bulut SD, Bozkurt A, Ozsahin A.
    Adv Ther; 2011 Apr 21; 28(4):341-8. PubMed ID: 21437763
    [Abstract] [Full Text] [Related]

  • 4. Augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder using adjunctive olanzapine: a placebo-controlled trial.
    Bystritsky A, Ackerman DL, Rosen RM, Vapnik T, Gorbis E, Maidment KM, Saxena S.
    J Clin Psychiatry; 2004 Apr 21; 65(4):565-8. PubMed ID: 15119922
    [Abstract] [Full Text] [Related]

  • 5. A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder.
    Bloch MH, Landeros-Weisenberger A, Kelmendi B, Coric V, Bracken MB, Leckman JF.
    Mol Psychiatry; 2006 Jul 21; 11(7):622-32. PubMed ID: 16585942
    [Abstract] [Full Text] [Related]

  • 6. Cognitive-behavioral therapy vs risperidone for augmenting serotonin reuptake inhibitors in obsessive-compulsive disorder: a randomized clinical trial.
    Simpson HB, Foa EB, Liebowitz MR, Huppert JD, Cahill S, Maher MJ, McLean CP, Bender J, Marcus SM, Williams MT, Weaver J, Vermes D, Van Meter PE, Rodriguez CI, Powers M, Pinto A, Imms P, Hahn CG, Campeas R.
    JAMA Psychiatry; 2013 Nov 21; 70(11):1190-9. PubMed ID: 24026523
    [Abstract] [Full Text] [Related]

  • 7. Memantine augmentation in treatment-resistant obsessive-compulsive disorder: an open-label trial.
    Aboujaoude E, Barry JJ, Gamel N.
    J Clin Psychopharmacol; 2009 Feb 21; 29(1):51-5. PubMed ID: 19142108
    [Abstract] [Full Text] [Related]

  • 8. Agomelatine efficacy in treatment resistant obsessive-compulsive disorder: A randomized controlled trial.
    Nejati A, Bazrafshan A, Mosavat SH.
    Int J Psychiatry Med; 2024 Sep 21; 59(5):545-555. PubMed ID: 38156645
    [Abstract] [Full Text] [Related]

  • 9. A double-blind, randomized, placebo-controlled trial of quetiapine addition in patients with obsessive-compulsive disorder refractory to serotonin reuptake inhibitors.
    Denys D, de Geus F, van Megen HJ, Westenberg HG.
    J Clin Psychiatry; 2004 Aug 21; 65(8):1040-8. PubMed ID: 15323587
    [Abstract] [Full Text] [Related]

  • 10. Olanzapine augmentation for treatment-resistant obsessive-compulsive disorder.
    Koran LM, Ringold AL, Elliott MA.
    J Clin Psychiatry; 2000 Jul 21; 61(7):514-7. PubMed ID: 10937610
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Combined fluvoxamine and extended-release methylphenidate improved treatment response compared to fluvoxamine alone in patients with treatment-refractory obsessive-compulsive disorder: A randomized double-blind, placebo-controlled study.
    Zheng H, Jia F, Han H, Wang S, Guo G, Quan D, Li G, Huang H.
    Eur Neuropsychopharmacol; 2019 Mar 21; 29(3):397-404. PubMed ID: 30595354
    [Abstract] [Full Text] [Related]

  • 13. Risperidone and haloperidol augmentation of serotonin reuptake inhibitors in refractory obsessive-compulsive disorder: a crossover study.
    Li X, May RS, Tolbert LC, Jackson WT, Flournoy JM, Baxter LR.
    J Clin Psychiatry; 2005 Jun 21; 66(6):736-43. PubMed ID: 15960567
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Is circadian rhythm disruption important in obsessive-compulsive disorder (OCD)? A case of successful augmentation with agomelatine for the treatment of OCD.
    da Rocha FF, Correa H.
    Clin Neuropharmacol; 2011 Jun 21; 34(4):139-40. PubMed ID: 21768800
    [Abstract] [Full Text] [Related]

  • 16. Escitalopram in the treatment of patients with schizophrenia and obsessive-compulsive disorder: an open-label, prospective study.
    Stryjer R, Dambinsky Y, Timinsky I, Green T, Kotler M, Weizman A, Spivak B.
    Int Clin Psychopharmacol; 2013 Mar 21; 28(2):96-8. PubMed ID: 23211492
    [Abstract] [Full Text] [Related]

  • 17. Amantadine augmentation therapy for obsessive compulsive patients resistant to SSRIs-an open-label study.
    Stryjer R, Budnik D, Ebert T, Green T, Polak L, Weizman S, Spivak B.
    Clin Neuropharmacol; 2014 Mar 21; 37(3):79-81. PubMed ID: 24824662
    [Abstract] [Full Text] [Related]

  • 18. Memantine augmentation of sertraline in the treatment of symptoms and executive function among patients with obsessive-compulsive disorder: A double-blind placebo-controlled, randomized clinical trial.
    Askari S, Mokhtari S, Shariat SV, Shariati B, Yarahmadi M, Shalbafan M.
    BMC Psychiatry; 2022 Jan 12; 22(1):34. PubMed ID: 35022014
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Ondansetron augmentation in treatment-resistant obsessive-compulsive disorder: a preliminary, single-blind, prospective study.
    Pallanti S, Bernardi S, Antonini S, Singh N, Hollander E.
    CNS Drugs; 2009 Dec 12; 23(12):1047-55. PubMed ID: 19958042
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 32.